Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.67 |
| ▸ | CES1 | P23141 | 3/20 | 0.57 |
| ▸ | TGM2 | P21980 | 3/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.45 |
| ▸ | ROS1 | P08922 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | PPOX | P50336 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1291050 | 0.89 | CHEK1 (0.65) | CHEK1CES1TGM2LRRK2ACVR1 | |
| SCHEMBL1291059 | 0.89 | CHEK1 (0.65) | CHEK1CES1TGM2LRRK2ACVR1 | |
| SCHEMBL30972546 | 0.84 | TGM2 (0.77) | CES1TGM2LRRK2ACVR1ROS1 | |
| SCHEMBL24665688 | 0.82 | TGM2 (0.68) | CES1TGM2LRRK2ACVR1ROS1 | |
| SCHEMBL11021675 | 0.82 | TGM2 (0.59) | CHEK1CES1TGM2LRRK2PPOX | |
| SCHEMBL11890572 | 0.82 | TGM2 (0.59) | CHEK1CES1TGM2LRRK2PPOX | |
| SCHEMBL25666640 | 0.81 | CSNK1G1 (0.67) | CHEK1CES1TGM2LRRK2ACVR1 | |
| SCHEMBL20442466 | 0.81 | CHEK1 (0.67) | CHEK1CES1TGM2LRRK2ACVR1 | |
| SCHEMBL31139641 | 0.80 | CES1 (0.77) | CHEK1CES1TGM2LRRK2PPOX | |
| SCHEMBL1368761 | 0.80 | CHEK1 (1.00) | CHEK1CES1TGM2LRRK2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200200765-A1 | BROAD SPECTRUM GPCR BINDING AGENTS | PROMEGA CORPORATION | 2020-06-25 | — | — | US | disclosed |
| WO-2020117954-A2 | BROAD SPECTRUM GPCR BINDING AGENTS | PROMEGA CORPORATION (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20100129473-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-7622461-B2 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090239840-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| EP-2088147-A1 | Dibenzo-condensed azepine, diazepine, oxazepine and thiazepine derivatives as muscarinic agonists and methods of treatment of neuropsychiatric disorders | Arcadia Pharmaceuticals Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7550454-B2 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7517871-B2 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7491715-B2 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20070197502-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | EK FREDRIK | 2007-08-23 | — | — | US | disclosed |
| US-20060252744-A1 | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents | ACADIA PHARMACEUTICALS INC. | 2006-11-09 | — | — | US | disclosed |
| US-20060199798-A1 | Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | EK FREDRIK | 2006-09-07 | — | — | US | disclosed |
| US-20060194784-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | EK FREDRIK | 2006-08-31 | — | — | US | disclosed |
| US-20050192268-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS INC. | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129473-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CHRM4, CHRM5, CHRM1 | CHEK1 889/4885CES1 858/4885TGM2 1791/4885 |
| US-20070197502-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CHRM4, CHRM5, CHRM1 | CHEK1 872/4885CES1 841/4885TGM2 1781/4885 |
| US-20060252744-A1 | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents | DRD3, DRD2, PNMT | CHEK1 2397/4885CES1 3580/4885TGM2 2157/4885 |
| US-20200200765-A1 | BROAD SPECTRUM GPCR BINDING AGENTS | GPR139, GPR4, GPR3 | CHEK1 2264/4885CES1 3394/4885TGM2 1348/4885 |
| US-20060194784-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | CHRM4, CHRM5, CHRNA10 | CHEK1 1568/4885CES1 1106/4885TGM2 1463/4885 |
| US-20090239840-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CHRM4, CHRM5, CHRNA10 | CHEK1 1568/4885CES1 1106/4885TGM2 1463/4885 |
| US-20050192268-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | CHRM4, CHRM5, CHRNA10 | CHEK1 1568/4885CES1 1106/4885TGM2 1463/4885 |
| US-20060199798-A1 | Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | OPRL1, CHRM4, CNR1 | CHEK1 1744/4885CES1 1080/4885TGM2 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.